Parathyroid hormone therapy for hypoparathyroidism

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 29, Issue 1, 2015, Pages 47-55

  Cusano, Natalie E ^a   Rubin, Mishaela R ^a   Bilezikian, John P ^a   Dorothy, L ^a   Silberberg, Daniel H ^a  

^a Columbia University ^*  (United States)

Author keywords

Hypoparathyroidism; Parathyroid hormone; PTH(1 34); PTH(1 84); Teriparatide

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHORUS; TETRACYCLINE; THIAZIDE DIURETIC AGENT; VITAMIN D;

BONE BIOPSY; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CORTICAL BONE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPOPARATHYROIDISM; KIDNEY DISTAL TUBULE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; TRABECULAR BONE; VITAMIN SUPPLEMENTATION; TREATMENT OUTCOME;

CALCIUM; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPARATHYROIDISM; PARATHYROID HORMONE; TREATMENT OUTCOME; VITAMIN D;

EID: 84927934942     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.09.001     Document Type: Review

References (36)

1. Bilezikian JP, Khan A, Potts Jr. JT, et al. Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, targetorgan involvement, treatment, and challenges for future research. J Bone Mineral Res 2011; 26: 2317-37.
2. Cusano NE, Rubin MR, Sliney Jr. J, et al. Mini-review: New therapeutic options in hypoparathyroidism. Endocrine 2012; 41: 410-4.
3. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med 2008; 359: 391-403.
4. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metabolism 2012; 97: 4507-14.
5. Mendonca ML, Pereira FA, Nogueira-Barbosa MH, et al. Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord 2013; 13: 1.
6. Underbjerg L, Sikjaer T, Mosekilde L, et al. Post-surgical hypoparathyroidism - risk of fractures, psychiatric diseases, cancer, cataract, and infections. J Bone Mineral Res 2014 May 7. http://dx.doi.org/10.1002/jbmr.2273 [Epub ahead of print].
7. Powers J, Joy K, Ruscio A, et al. Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Mineral Res 2013; 28: 2570-6.
8. Pearce SH, Williamson C, Kifor O, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996; 335: 1115-22.
9. Sunthornthepvarakul T, Churesigaew S, Ngowngarmratana S. A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J Clin Endocrinol Metabolism 1999; 84: 3792-6.
10. Albright F, Ellsworth R. Studies on the physiology of the parathyroid glands: I. calcium and phosphorus studies on a case of idiopathic hypoparathyroidism. J Clin Investestigation 1929; 7: 183-201.
11. Rubin MR, Sliney Jr. J, McMahon DJ, et al. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int 2010; 21: 1927-34.
12. Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH (1-84) : A prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metabolism 2013; 98: 137-44.
13. Sikjaer T, Rejnmark L, Rolighed L, et al. The effect of adding PTH (1-84) to conventional treatment of hypoparathyroidism: A randomized, placebo-controlled study. J Bone Mineral Res 2011; 26: 2358-70.
14. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE) : A double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes & Endocrinol 2013; 1: 275-83.
15. Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metabolism 2003; 88: 4214-20.
16. Winer KK, Sinaii N, Reynolds J, et al. Long-term treatment of 12 children with chronic hypoparathyroidism: A randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metabolism 2010; 95: 2680-8.
17. Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: A randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metabolism 2011; 97: 391-9.
18. Gafni RI, Brahim JS, Andreopoulou P, et al. Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Mineral Res 2012; 27: 1811-20.
19. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 2002; 146: 215-22.
20. Cusano NE, Rubin MR, McMahon DJ, et al. The effect of PTH (1-84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metabolism 2013; 98: 2356-61.
21. Sikjaer T, Rolighed L, Hess A, et al. Effects of PTH (1-84) therapy on muscle function and quality of life in hypoparathyroidism: Results from a randomized controlled trial. Osteoporos Int 2014; 25: 1717-26.
22. Cusano NE, Rubin MR, McMahon DJ, et al. PTH (1-84) is associated with improved quality of life in hypoparathyroidism through 5 Years of Therapy. J Clin Endocrinol Metabolism 2014 Aug 19. http://dx.doi.org/jc20141500 [Epub ahead of print].
23. Rubin MR, Dempster DW, Sliney Jr. J, et al. PTH (1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Mineral Res 2011; 26: 2727-36.
24. Rubin MR, Dempster DW, Zhou H, et al. Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Mineral Res 2008; 23: 2018-24.
25. Sikjaer T, Rejnmark L, Thomsen JS, et al. Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH (1-84) : A randomized controlled study. J Bone Mineral Res 2012; 27: 781-8.
26. Recker RR, Bare SP, Smith SY, et al. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84. Bone 2009; 44: 113-9.
27. Jobke B, Muche B, Burghardt AJ, et al. Teriparatide in bisphosphonate-resistant osteoporosis: Microarchitectural changes and clinical results after 6 and 18 months. Calcif Tissue Int 2011; 89: 130-9.
28. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Mineral Res 2001; 16: 1846-53.
29. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30: 312-21.
30. Jolette J, Wilker CE, Smith SY, et al. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 2006; 34: 929-40.
31. Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J Bone Mineral Res 2012; 27: 2429-37.
32. Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: A decade of experience. J Bone Mineral Res 2012; 27: 2419-28.
33. Daddona PE, Matriano JA, Mandema J, et al. Parathyroid hormone (1-34)-coated microneedle patch system: Clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res 2011; 28: 159-65.
34. Hattersley G, Bilezikian JP, Guerriero J, et al. Bone anabolic efficacy and safety of BA058, a novel analog of hPTHrP: Results from a phase 2 clinical trial in postmenopausal women with osteoporosis. In: The endocrine Society's 94th annual meeting and Expo. Houston, TX OR08-1; 2012.
35. Winer KK, Yanovski JA, Sarani B, et al. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metabolism 1998; 83: 3480-6.
36. Winer KK, Sinaii N, Peterson D, et al. Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metabolism 2008; 93: 3389-95.